Related Experiment Video
Updated: Jun 17, 2026
08:25
Transverse Aortic Constriction in Mice
Published on: April 21, 2010
Tissue-specific modulation of beta-adducin transcripts in Milan hypertensive rats
Grazia Tripodi1, Rossana Modica, Cristina Reina
1Prassis-Sigma Tau Research Institute, Via Forlanini, 1, 20029 Settimo Milanese, Milan, Italy. grazia.tripodi@prassis.it
Biochemical and Biophysical Research Communications
|March 21, 2003
Summary
Genetic variants in adducins are linked to hypertension. This study found altered beta-adducin expression in key cardiovascular tissues of hypertensive rats, suggesting its role in the disease.
Area of Science:
- Genetics
- Molecular Biology
- Cardiovascular Research
Background:
- Adducins are cytoskeleton proteins involved in blood pressure regulation.
- Genetic variants in adducins are associated with primary hypertension in humans and Milan hypertensive rats (MHS).
Purpose of the Study:
- To identify novel adducin isoforms and analyze adducin gene family expression in MHS rats.
- To investigate tissue-specific expression changes of adducin transcripts during hypertension development in MHS rats.
Main Methods:
- Identification of a rat beta 4 adducin alternative splicing isoform.
- Development of a quantitative real-time PCR assay for adducin gene expression analysis.
- Tissue expression analysis in kidney, left ventricle, and large arteries of MHS and normotensive MNS rats.
Main Results:
- Beta-adducin transcripts showed tissue-specific modulation during hypertension development in MHS rats.
- A significant decrease in renal outer medulla beta-adducin was observed during the prehypertensive phase.
- Hypertension was associated with decreased beta-adducin in femoral arteries and increased levels in the left ventricle.
- The beta 4 adducin isoform was drastically reduced in all MHS tissues studied.
Conclusions:
- Beta-adducin transcript levels are altered in a tissue-specific manner during the development of hypertension in MHS rats.
- The observed alterations in beta-adducin expression, particularly the reduction of beta 4-Add, may contribute to the hypertensive phenotype in MHS rats.
More Related Videos
Related Concept Videos
01:31Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
01:26Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...